Timing note: July 23, 2026 is today, not tomorrow. Quest is scheduled to release results before the market opens and hold its earnings call at 8:30 a.m. ET on Thursday, July 23, 2026. This preview is based on information available before the Q2 release appeared in the financial-document database.
Quest enters Q2 with strong operating momentum but a more demanding stock setup. First-quarter organic growth was unusually strong, management raised full-year guidance, and the shares closed July 22 at $209.87—about 21% above the first trading day of 2026. The stock now trades at roughly 19.6× the midpoint of 2026 adjusted EPS guidance.
Accordingly, the key question is not simply whether Quest reports another solid quarter. Investors need evidence that:
A revenue or EPS beat without strong underlying volume quality and constructive guidance may not be enough after the stock’s run.
| Metric | Q2 2025 result | Q1 2026 result | Current FY2026 guidance |
|---|---|---|---|
| Revenue | $2.761B | $2.895B | $11.78B–$11.90B |
| Revenue growth | 15.2% | 9.2% | 6.8%–7.8% |
| Organic revenue growth | 5.2% | 9.0% | Not separately guided |
| Requisition volume growth | 16.3% | 10.9% | — |
| Organic volume growth | 2.1% | 10.8% | — |
| Revenue per requisition | (0.4)% | (1.3)% | — |
| Adjusted operating margin | 16.9% | 15.4% | Expected to expand YoY |
| Adjusted EPS | $2.62 | $2.50 | $10.63–$10.83 |
| Operating cash flow | $544M | $278M | Approximately $1.75B |
Management said just over 49% of full-year revenue and EPS should be generated in the first half. Applying approximately 49%–49.5% to the midpoint of guidance produces a rough management-cadence-implied Q2 range of:
That would represent roughly 5%–7% year-over-year growth in both revenue and adjusted EPS.
These figures are not Wall Street consensus estimates; they are an inference from management’s annual guidance and first-half cadence commentary.
Quest reported 10.8% organic volume growth in Q1, but approximately seven percentage points came from the new Corewell Health relationship and the Fresenius Medical Care dialysis business. Excluding those two relationships, organic volume grew 3.8%.
That 3.8% underlying figure is arguably the cleanest measure of business health. Investors should focus on whether it:
Quest had embedded an approximately 30-basis-point revenue headwind from ACA-related disenrollment in its annual outlook, although management said it had not yet seen a meaningful impact in Q1. An update here could affect the second-half outlook.
Headline revenue per requisition declined 1.3% in Q1 because Corewell and Fresenius contribute a higher proportion of routine, lower-value tests. Excluding those relationships, revenue per requisition increased approximately 2.5%, driven by more tests per requisition and favorable advanced-diagnostics mix.
For Q2, investors should separate these two trends:
Management said reimbursement was approximately flat in Q1. Thus, mix and tests per requisition—not pricing—are currently the main levers.
Margin is likely the most important financial variable in the release.
Quest’s adjusted operating margin was 15.4% in Q1, up only ten basis points despite 9% organic revenue growth. Productivity and revenue growth offset wage inflation and adverse weather, but several additional pressures begin to build in Q2:
There are offsets. Quest targets approximately 3% annual savings and productivity improvement through Invigorate, and management says automation and AI are producing measurable productivity gains. The margin profile of the large new relationships should also improve with scale, although management indicated that the more meaningful improvement—particularly for Fresenius—comes in the second half.
A good Q2 would combine healthy volume with stable or improving underlying margins. Strong revenue accompanied by a material margin miss would raise questions about the economics of the new business wins.
Quest’s direct-to-consumer business grew in the high-20% range in Q1, while its broader consumer partnerships grew even faster. These include wellness platforms and wearable-device collaborations.
Management says these businesses generate margins at or slightly above the company average because much of the activity is cash-pay or client-billed, with fewer denials and patient concessions.
Watch for:
Quest reported double-digit growth in several priority clinical areas, including brain health and cardiometabolic testing. Its Alzheimer’s testing business more than doubled year over year in Q1.
Important updates could include:
Haystack remains strategically important but is still early. Investors should listen for progress on MolDX review, Medicare Advantage reimbursement, test orders and the timeline toward reduced dilution or breakeven. Management previously disclosed baseline and monitoring reimbursement benchmarks of approximately $3,900 and $800, respectively.
Current 2026 guidance calls for:
Quest already raised revenue and EPS guidance after Q1. Another increase would reinforce the view that utilization, consumer testing and new enterprise relationships are outperforming initial assumptions.
Given the stock’s appreciation, a simple reiteration may be viewed as less compelling unless management clearly identifies conservatism or upside opportunities.
Q1 operating cash flow declined to $278 million from $314 million because of payment timing and higher bonus payments, despite stronger operating income. That leaves investors looking for a meaningful Q2 normalization toward the approximately $1.75 billion annual target.
Quest had $393 million of cash and $1.3 billion of available credit capacity at the end of Q1. It also had $1.4 billion remaining under its share-repurchase authorization, although it repurchased no stock during Q1.
In May, Quest issued $500 million of 5.0% senior notes due 2036, potentially replacing $500 million of 3.45% notes that matured June 1. That refinancing extends the maturity profile but carries a higher coupon. Investors should check whether updated interest-expense guidance fully reflects the transaction and whether capital priorities remain tilted toward acquisitions rather than repurchases.
The M&A pipeline remains strategically relevant, particularly hospital outreach assets and additional collaborative lab arrangements. Current guidance excludes prospective acquisitions.
Quest participated in the 2026 PAMA data-collection process and has argued that broader hospital-lab participation could produce more representative—and potentially higher—Medicare laboratory rates. Management was also advocating passage of the RESULTS Act, which could preserve rates for 2027.
Investors should look for:
Management previously said Quest had immaterial exposure to the specific high-growth testing categories cited in the government’s CRUSH initiative. Still, any movement toward broader laboratory prior authorization could create administrative burdens. The call may provide an updated assessment of this risk.
The central debate is whether Quest’s strong top-line growth is translating into durable, higher-quality earnings growth.
The Q2 headline numbers matter, but investors should place greater weight on four disclosures:
Quest’s strategic positioning remains favorable: it is gaining enterprise business, benefiting from consumer-driven testing and participating in expanding advanced-diagnostics markets. But with the shares up roughly 21% year to date and valued near 20× midpoint guidance, the report likely needs to demonstrate not merely growth, but strong underlying utilization, margin conversion and additional earnings upside.
Research base: Quest’s Q1 2026 earnings release, earnings call and Form 10-Q; Q2 2025 earnings release; subsequent debt filings; the July 23 earnings announcement; and market prices through July 22, 2026.